Cargando…

Efficacy and safety of oral doxercalciferol in the management of secondary hyperparathyroidism in chronic kidney disease stage 4

This study was carried out to evaluate the efficacy and safety of doxercalciferol as therapy for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) stage 4 in a prospective clinical trial. A total of 35 CKD-4 patients who had a baseline parathyroid hormone (iPTH) >...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dheerendra, P. C., Sakhuja, V., Kohli, H. S., Jha, V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3741971/ https://www.ncbi.nlm.nih.gov/pubmed/23960343 http://dx.doi.org/10.4103/0971-4065.114492

Ejemplares similares

Comparison of the Pharmacological Effects of Paricalcitol and Doxercalciferol on the Factors Involved in Mineral Homeostasis
por: Wu-Wong, J. Ruth, et al.
Publicado: (2010)

Osteocytic Protein Expression Response to Doxercalciferol Therapy in Pediatric Dialysis Patients
por: Pereira, Renata C., et al.
Publicado: (2015)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Secondary Hyperparathyroidism in Chronic Kidney Disease: Pathophysiology and Management
por: Habas, Elmukhtar, et al.
Publicado: (2021)

Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease
por: Han, Tianzhao, et al.
Publicado: (2013)

Recent advances in understanding and managing secondary hyperparathyroidism in chronic kidney disease
por: Rodríguez-Ortiz, María E., et al.
Publicado: (2020)

Efficacy and safety of cinacalcet compared with other treatments for secondary hyperparathyroidism in patients with chronic kidney disease or end-stage renal disease: a meta-analysis
por: Sun, Yiting, et al.
Publicado: (2020)

Indication and efficacy of PEIT in the management of secondary hyperparathyroidism
por: Koiwa, Fumihiko, et al.
Publicado: (2008)

Secondary hyperparathyroidism among Nigerians with chronic kidney disease
por: Gimba, Zumnan M, et al.
Publicado: (2018)

A New Look at the Most Successful Prodrugs for Active Vitamin D (D Hormone): Alfacalcidol and Doxercalciferol
por: Kubodera, Noboru
Publicado: (2009)

Noninvasive assessment of bone health in Indian patients with chronic kidney disease
por: Jabbar, Z., et al.
Publicado: (2013)

Parathyroid Cell Proliferation in Secondary Hyperparathyroidism of Chronic Kidney Disease
por: Naveh-Many, Tally, et al.
Publicado: (2020)

Bone mineral density in patients with end-stage renal disease and its evolution after kidney transplantation
por: Govindarajan, S., et al.
Publicado: (2011)

Surgical Management of Secondary Hyperparathyroidism
por: Steinl, Gabrielle K., et al.
Publicado: (2020)

Association of Secondary Hyperparathyroidism with Hemoglobin Level in Patients with Chronic Kidney Disease
por: Chutia, Happy, et al.
Publicado: (2013)

Secondary and Tertiary Hyperparathyroidism in Chronic Kidney Disease: An Endocrine and Renal Perspective
por: Chandran, Manju, et al.
Publicado: (2019)

Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease
por: Xu, Yang, et al.
Publicado: (2021)

Complications after radiofrequency ablation of hyperparathyroidism secondary to chronic kidney disease
por: Lin, Li-Ping, et al.
Publicado: (2023)

Outcomes of Secondary Hyperparathyroidism in Chronic Kidney Disease and the Direct Costs of Treatment
por: Joy, Melanie S., et al.
Publicado: (2007)

Cost-effectiveness analysis of intravenous paricalcitol vs. oral calcitriol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Cardoso, Marilia Mastrocolla de Almeida, et al.
Publicado: (2022)

Efficacy and safety of evocalcet in treatment of secondary hyperparathyroidism in chronic kidney disease on hemodialysis patients: A protocol for a systematic review and meta-analysis
por: Xie, Jing, et al.
Publicado: (2020)

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
por: Bushinsky, David A, et al.
Publicado: (2019)

One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism
por: Bushinsky, David A, et al.
Publicado: (2019)

Efficacy and safety of radiofrequency ablation for primary and secondary hyperparathyroidism: a retrospective study
por: Qiu, Xinguang, et al.
Publicado: (2023)

Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis
por: Pérez-Ricart, Ariadna, et al.
Publicado: (2016)

Limited usefulness of calcimimetics for secondary hyperparathyroidism in non-dialysis chronic kidney disease
por: Abbas, Fizza, et al.
Publicado: (2019)

Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease
por: Friedl, Claudia, et al.
Publicado: (2017)

Efficacy of basiliximab induction in poorly matched living donor renal transplantation
por: Gundlapalli, S., et al.
Publicado: (2013)

The impact of secondary hyperparathyroidism on the efficacy of antiresorptive therapy
por: Kincse, Gyöngyvér, et al.
Publicado: (2012)

Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis
por: Yokoyama, Keitaro, et al.
Publicado: (2019)

Oral manifestations of secondary hyperparathyroidism: A case report
por: Kakade, Sunita P., et al.
Publicado: (2015)

Pin1 and secondary hyperparathyroidism of chronic kidney disease: gene polymorphisms and protein levels
por: Zhao, Yu, et al.
Publicado: (2016)

Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
por: Xu, Wei, et al.
Publicado: (2020)

Evaluation of Therapies for Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney Disease
por: Strugnell, Stephen A., et al.
Publicado: (2023)

Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease
por: Ketteler, Markus, et al.
Publicado: (2021)

Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
por: Hauber, Brett, et al.
Publicado: (2017)

Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis
por: Shigematsu, Takashi, et al.
Publicado: (2020)

Utilization of parathyroidectomy for secondary hyperparathyroidism in end-stage renal disease
por: Konstantinidis, Ioannis, et al.
Publicado: (2013)

Effects and Safety of Calcimimetics in End Stage Renal Disease Patients with Secondary Hyperparathyroidism: A Meta-Analysis
por: Zhang, Qian, et al.
Publicado: (2012)

The Pathophysiology of Secondary Hyperparathyroidism and the Consequences of Uncontrolled Mineral Metabolism in Chronic Kidney Disease: The Role of COSMOS
por: Cannata-Andía, Jorge B., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_e65dogcaujk8e1n343guc9mhr1